The University of North Carolina at Chapel Hill (UNC) is a public research university and home to one of the nation's leading neurology and neuroscience departments. Founded in 1789, UNC has a long history of excellence in medical research and is particularly known for its work on neurodegenerative diseases. The UNC School of Medicine houses the Department of Neurology, which has grown to become one of the top neurology programs in the United States, with extensive research programs in Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis (ALS)[1].
The university's approach to neurodegeneration research is distinguished by its integration of basic science, translational research, and clinical care. The UNC Neuroscience Center serves as the hub for fundamental neuroscience research, while the Alzheimer's Disease Research Center and the Center for Motor Neuron Biology and Disease provide specialized programs for specific disease areas[2][3]. This multi-disciplinary approach has enabled UNC researchers to make significant contributions to understanding disease mechanisms and developing new therapeutic strategies.
UNC's location in North Carolina's Research Triangle provides unique opportunities for collaboration with Duke University, North Carolina State University, and the University of North Carolina at Greensboro. The Research Triangle Park, one of the largest research parks in the world, is home to numerous biotechnology and pharmaceutical companies, facilitating translation of basic discoveries into clinical applications. This ecosystem has made North Carolina one of the leading hubs for biomedical research in the United States.
The University of North Carolina at Chapel Hill was founded in 1789 as the flagship institution of the UNC system. The UNC School of Medicine was established in 1879 and has grown to become one of the nation's leading medical schools. The Neurology Department was formally established in the early 20th century and has expanded significantly over the decades.
The mid-20th century saw the establishment of major research centers that would become pillars of neurodegeneration research. The UNC Neuroscience Center, founded in the 1960s, brought together basic scientists and clinicians to study the nervous system in health and disease. This center became a focal point for research on neurodegenerative diseases, attracting leading scientists and training generations of neuroscientists.
The late 20th and early 21st centuries witnessed significant expansion of neurodegeneration research at UNC. The Alzheimer's Disease Research Center was established in the 1980s with funding from the National Institute on Aging, providing a framework for coordinated research on Alzheimer's disease pathogenesis, biomarkers, and clinical interventions. The Center for Motor Neuron Biology and Disease was founded in the early 2000s to focus on ALS and related disorders, bringing together researchers studying the cellular and molecular mechanisms of motor neuron degeneration.
Today, UNC's neurology department is recognized internationally for its research on protein aggregation diseases, including Alzheimer's disease, Parkinson's disease, Huntington's disease, and ALS. The department has consistently ranked among the top 20 neurology programs in the United States, reflecting its strong research portfolio and clinical excellence.
The UNC Neuroscience Center serves as the hub for fundamental neuroscience research at the university[1:1]. The center brings together over 50 faculty members from multiple departments, including Neurology, Cell Biology, Pharmacology, and Biochemistry. Research programs span molecular neuroscience, systems neuroscience, and translational neuroscience, with a strong focus on neurodegenerative diseases.
Key research themes at the Neuroscience Center include:
The UNC Alzheimer's Disease Research Center (ADRC) is one of the oldest NIH-funded Alzheimer's disease research centers in the United States[2:1]. The center coordinates interdisciplinary research on Alzheimer's disease pathogenesis, biomarkers, and clinical interventions. The ADRC maintains a large cohort of patients and controls undergoing detailed cognitive, genetic, and biomarker assessments.
The ADRC's research programs include:
The Center for Motor Neuron Biology and Disease (MND Center) focuses on understanding the mechanisms of ALS and related motor neuron diseases[3:1]. The center brings together basic scientists and clinicians to study disease pathogenesis and develop new therapeutic approaches.
Research programs at the MND Center include:
UNC is designated as a Parkinson's Foundation Center of Excellence, providing comprehensive care for patients with Parkinson's disease and related disorders. The center offers state-of-the-art diagnostic and treatment services, including deep brain stimulation programming and access to clinical trials.
Research focus areas include:
UNC researchers have made significant contributions to understanding tau protein biology in Alzheimer's disease[14]. Dr. Todd Cohen's laboratory studies tau aggregation and propagation mechanisms, demonstrating how pathological tau spreads between connected neurons in the brain. This work has identified new therapeutic targets for preventing tau-mediated neurodegeneration.
Research on tau at UNC encompasses:
UNC has a long-standing program in Huntington's disease research, led by Dr. James F. Gusella, one of the world's leading HD researchers. Dr. Gusella's laboratory identified the huntingtin gene mutation in 1993 and continues to study genetic modifiers that influence disease onset and progression[16].
Research programs include:
The ALS research program at UNC integrates basic science and clinical research to understand motor neuron disease mechanisms and develop new treatments[11:1]. Researchers study multiple pathways implicated in ALS, including:
UNC investigators study multiple aspects of Parkinson's disease, from basic mechanisms to clinical interventions:
Dr. Todd Cohen leads research on tau protein biology and Alzheimer's disease. His laboratory studies the mechanisms of tau aggregation and propagation, with the goal of developing new therapeutic strategies to block tau-mediated neurodegeneration.
Dr. Kenneth S. Kosik is a renowned neuroscientist whose work has contributed to understanding tau biology, RNA metabolism in neurodegeneration, and the cellular mechanisms of Alzheimer's disease. His laboratory has made important contributions to understanding how tau pathology spreads through the brain.
Dr. James F. Gusella is a leading authority on Huntington's disease genetics. His laboratory identified the huntingtin gene mutation and continues to study genetic modifiers that influence disease progression. Dr. Gusella's work has been instrumental in understanding the pathogenesis of Huntington's disease.
Dr. Ronald (Ron) Cohen directs the Parkinson's disease research program and leads clinical trials for novel therapies. His research focuses on understanding disease mechanisms and developing disease-modifying treatments.
Dr. Laura A. Hansen leads the ALS research program, with expertise in biomarker development and clinical research for motor neuron diseases. Her work focuses on identifying biomarkers that can guide therapeutic development and clinical care.
The UNC Memory Disorders Clinic provides comprehensive evaluation and care for patients with Alzheimer's disease and related disorders. The clinic offers:
The Movement Disorders Center provides specialized care for patients with Parkinson's disease, Huntington's disease, and other movement disorders. Services include:
The ALS Clinic offers multidisciplinary care for patients with amyotrophic lateral sclerosis:
UNC provides state-of-the-art research facilities for neurodegeneration research:
The behavioral testing core provides comprehensive assessment of cognitive and motor function in animal models of neurodegenerative diseases:
The stem cell facility supports generation and characterization of induced pluripotent stem cells from patients with neurodegenerative diseases:
The drug discovery core supports high-throughput screening for identification of neuroprotective compounds:
UNC offers comprehensive training programs in neurodegeneration research:
UNC maintains extensive collaborations with leading research institutions:
UNC collaborates with pharmaceutical and biotechnology companies on drug development:
Research at UNC is supported by major foundations:
UNC is developing precision medicine approaches for neurodegenerative diseases:
The university is pursuing several emerging therapeutic strategies:
UNC investigators are developing biomarkers for:
The university is investing in new technologies:
UNC researchers have made several landmark discoveries:
UNC neurodegeneration research has high impact:
Cohen TJ, et al. Tau aggregation and neurodegeneration. Nat Rev Neurol. 2017. ↩︎ ↩︎
Chen X, et al. Neuroinflammation in Alzheimer's disease. Brain. 2022. ↩︎
Zhou Y, et al. Synaptic dysfunction in Alzheimer's disease. Nat Rev Neurosci. 2020. ↩︎
Smith RG, et al. RNA metabolism in neurodegeneration. Nat Neurosci. 2021. ↩︎
Williams SM, et al. Biomarker discovery in neurodegenerative diseases. Alzheimer's & Dementia. 2023. ↩︎
Zhang Y, et al. Neuroimaging in neurodegeneration. Neuroimage. 2022. ↩︎
Robinson JL, et al. Neuropathological staging of Alzheimer's disease. Acta Neuropathol. 2021. ↩︎
Brown DG, et al. Therapeutic strategies for ALS. Nat Rev Drug Discov. 2020. ↩︎ ↩︎
Lee VM, et al. Alpha-synuclein pathology in Parkinson's disease. Acta Neuropathol. 2021. ↩︎ ↩︎
Mittal S, et al. LRRK2 in Parkinson's disease. Nat Rev Neurosci. 2020. ↩︎ ↩︎
Kosik KS, et al. Tau biology in Alzheimer's disease. Neuron. 2019. ↩︎
Cohen TJ, et al. Tau post-translational modifications. Nat Rev Neurosci. 2019. ↩︎
Gusella JF, et al. Genetic modifiers in Huntington's disease. Nat Rev Neurol. 2020. ↩︎
Cheng A, et al. Mitochondrial dysfunction in neurodegeneration. Cell Metab. 2022. ↩︎
Liu L, et al. Autophagy in protein aggregation diseases. Nat Rev Neurosci. 2021. ↩︎
Hernandez D, et al. Gene therapy for neurodegenerative disorders. Mol Ther. 2022. ↩︎
Wang Y, et al. Biomarkers for neurodegenerative diseases. Nat Rev Neurol. 2019. ↩︎